Germany Archives

News and Trends 23 Jul 2015

MorphoSys’ blood disorder antibody reaches Phase I

MorphoSys AG seems to be sitting on a goldmine with its Human Combinatorial Antibody Library (HuCAL). The German giant snatched the second milestone payment from Novartis this year. The latter will now initiate a Phase I test for a HuCAL antibody designed to treat blood disorders. MorphoSys landed some big accounts in the past. Pfizer, Bayer, […]

July 23, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Biotech investors are back in Germany

Things are looking good for German Biotechs! At least, this is what the general mood at the international congress organized by the IZB on July 16th and 17th 2015 in Martinsried, near Munich, reflected. A bunch of international investors and decision makers gathered to show that the sector is picking up momentum again in Germany! The Innovation and Startup […]

July 23, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a common form of lung cancer. The drug candidate is paired with Qiagen’s therascreen EGRF test as a companion diagnostic test. There is no doubt: the future […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Jul 2015

Probiodrug bets on basic research with Harvard’s collaboration

Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School. Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s disease. […]

July 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jul 2015

Greenovation: Using Moss as a Drug Production Factory

Factor H, a key component of the immune system that is missing in patients suffering from atypical hemolytic uremic syndrome (aHUS) was effectively produced in the moss Physcomitrella patens. In collaboration with the University of Freiburg, Greenovation now aims to humanize the protein to suit it for clinical use. The complement system is part of […]

July 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

Sartorius Stedim Strengthens its Leadership in Biologics Manufacturing with Cellca’s Acquisition

Sartorius Stedim Biotech, a leading international supplier for the pharma and biotech industries, acquired the German-based Cellca last Wednesday. With this acquisition, Sartorius is strengthening its leading position as a biologics manufacturer. Last year, we visited Cellca during our first biotech Tour in Germany. The company is offering cell line and process development for large-scale protein production […]

July 6, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Jul 2015

CEVEC and Biotest to ease hemophilia patients’ lifes

A German collaboration seeks to treat the symptoms of hemophilia in patients suffering from the later. CEVEC and Biotest will join forces to produce and commercialize molecules using CEVEC’s expression platform. Biotest develops immunoglobulins, coagulation factors and albumins, based on human blood plasma, used for diseases of the immune and hematopoietic system. This makes it […]

July 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 2 Jul 2015

Roche and Evotec knocked down by their Alzheimer candidate

The progressive aging of the population in developed countries is turning Alzheimer into one of the biggest medical challenges of our times. And it looks like it is going to remain an unresolved problem for the moment, as Roche’s candidate failed its last clinical trial. The drug, developed in collaboration with German Evotec, didn’t meet […]

July 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jul 2015

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Everybody has already heard about Boston-based Moderna Therapeutics, the most highly valued venture-backed private Biotech, but CureVac, its German competitor, remains much more understated. This could rapidly change as CureVac just demonstrated that its technology beats Moderna’s. mRNA technologies could theoretically disrupt the whole drug industry. Imagine that you can directly inject mRNA into patients to make them produce their own therapeutic proteins. Unfortunately, […]

July 1, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Qiagen vs. Illumina, the next Big Fight in Next-gen Sequencing

Next-gen sequencing is a revolution. San Diego-based Illumina owns most of the market but German giant Qiagen is prepared to disrupt this fact by stepping in massively by the end of the year. The fight has only begun. Imagine you could sequence your genome to discover the disease you may have in the future. What if I told you, […]

June 30, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 29 Jun 2015

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Actelion has created a new start-up in the field of synthetic carbohydrate vaccines, together with the Max Planck Society. Actelion has made a funding commitment of up to €30M to back the new company, Vaxxilon. Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces discovered the first preclinical […]

June 29, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us